Difference between revisions of "Part:BBa K4175008"
(→Usage and Biology) |
|||
| Line 14: | Line 14: | ||
IL-6 is found to play a major role in the pathophysiology of cytokine release syndrome (CRS), the most common adverse effect during CAR-T therapy (Shimabukuro-Vornhagen et al., 2018; Xiao et al., 2021). The elevated IL-6 during CAR-T therapy is mostly released by monocyte/macrophage cell lines induced by target cell pyroptosis upon T cell killing (Norelli et al., 2018; Shimabukuro-Vornhagen et al., 2018). Therefore, we created this device to set a negative ‘switch’ for CAR expression in the case of high serum IL-6 level. We hoped that this would help prevent severe CRS. | IL-6 is found to play a major role in the pathophysiology of cytokine release syndrome (CRS), the most common adverse effect during CAR-T therapy (Shimabukuro-Vornhagen et al., 2018; Xiao et al., 2021). The elevated IL-6 during CAR-T therapy is mostly released by monocyte/macrophage cell lines induced by target cell pyroptosis upon T cell killing (Norelli et al., 2018; Shimabukuro-Vornhagen et al., 2018). Therefore, we created this device to set a negative ‘switch’ for CAR expression in the case of high serum IL-6 level. We hoped that this would help prevent severe CRS. | ||
| − | We expected that when the concentration of IL-6 is high, the binding of IL-6 with anti-IL-6 scFv would cause the Notch core domain to undergo proteolytic cleavages (Fig 1). As a result, the Gal4-KRAB domain would be released into the nucleus. We intended to express anti-CD19 CAR with UAS-pSV40 as the promoter in the CAR-T cells. Therefore, the DNA binding domain of Gal4 would bind to the UAS region, enabling the KRAB domain to inhibit the SV40 promoter. In this way, the expression of CAR would be inhibited. As the cytotoxicity effect of CAR-T cells would be weaker, the target cells would undergo less pyroptosis. Consequently, fewer monocytes/macrophages would be induced to release IL-6. The serum level of IL-6 would thus decrease. | + | We expected that when the concentration of IL-6 is high, the binding of IL-6 with anti-IL-6 scFv would cause the Notch core domain to undergo proteolytic cleavages (Fig 1). As a result, the Gal4-KRAB domain would be released into the nucleus. We intended to express anti-CD19 CAR with UAS-pSV40 as the promoter in the CAR-T cells (see <partinfo>BBa_K4175012</partinfo>). Therefore, the DNA binding domain of Gal4 would bind to the UAS region, enabling the KRAB domain to inhibit the SV40 promoter. In this way, the expression of CAR would be inhibited. As the cytotoxicity effect of CAR-T cells would be weaker, the target cells would undergo less pyroptosis. Consequently, fewer monocytes/macrophages would be induced to release IL-6. The serum level of IL-6 would thus decrease. |
When the concentration of IL-6 is low, IL-6R would fail to bind with IL-6 due to its low affinity. As the promoter upstream of CAR, pSV40, is a strong promoter, the CAR expression would be constitutive. Ideally, these would collectively allow the CAR-T cells to exert its cytotoxic effect under low IL-6 concentration (Fig 1). | When the concentration of IL-6 is low, IL-6R would fail to bind with IL-6 due to its low affinity. As the promoter upstream of CAR, pSV40, is a strong promoter, the CAR expression would be constitutive. Ideally, these would collectively allow the CAR-T cells to exert its cytotoxic effect under low IL-6 concentration (Fig 1). | ||
| − | Hopefully, these would help maintain the IL-6 level in a normal range during CAR-T therapy. | + | Hopefully, these would help maintain the IL-6 level in a normal range during CAR-T therapy. |
===References=== | ===References=== | ||
Revision as of 15:07, 10 October 2022
IL-6_scfv-Notch-Gal4KRAB
Sequence and Features
- 10INCOMPATIBLE WITH RFC[10]Illegal EcoRI site found at 60
Illegal XbaI site found at 271
Illegal PstI site found at 55
Illegal PstI site found at 1144
Illegal PstI site found at 1375
Illegal PstI site found at 1416
Illegal PstI site found at 1462
Illegal PstI site found at 2494 - 12INCOMPATIBLE WITH RFC[12]Illegal EcoRI site found at 60
Illegal PstI site found at 55
Illegal PstI site found at 1144
Illegal PstI site found at 1375
Illegal PstI site found at 1416
Illegal PstI site found at 1462
Illegal PstI site found at 2494 - 21INCOMPATIBLE WITH RFC[21]Illegal EcoRI site found at 60
Illegal BglII site found at 1052
Illegal BamHI site found at 76
Illegal XhoI site found at 19
Illegal XhoI site found at 1036 - 23INCOMPATIBLE WITH RFC[23]Illegal EcoRI site found at 60
Illegal XbaI site found at 271
Illegal PstI site found at 55
Illegal PstI site found at 1144
Illegal PstI site found at 1375
Illegal PstI site found at 1416
Illegal PstI site found at 1462
Illegal PstI site found at 2494 - 25INCOMPATIBLE WITH RFC[25]Illegal EcoRI site found at 60
Illegal XbaI site found at 271
Illegal PstI site found at 55
Illegal PstI site found at 1144
Illegal PstI site found at 1375
Illegal PstI site found at 1416
Illegal PstI site found at 1462
Illegal PstI site found at 2494
Illegal NgoMIV site found at 1288
Illegal NgoMIV site found at 2279
Illegal NgoMIV site found at 2414
Illegal AgeI site found at 1096 - 1000COMPATIBLE WITH RFC[1000]
Usage and Biology
This device incorporates anti-IL-6 scFv (BBa_K4175000), the Notch core domain (BBa_K4175001), and ZF_GAl4_KRAB (BBa_K2446037) (Fig 1).
In this device, IL-6-scFv is a sensor for serum IL-6 level. The Notch domain undergoes two proteolytic cleavages upon the binding of ligands to the extracellular domain, which allows the release of the intracellular domain into the cytoplasm and the nucleus (Morsut et al., 2016). Gal4KRAB is a transcriptional inhibitor, where Gal4 binds to UAS (Gal4-binding region) in DNA and KRAB binds to the promoter attached to UAS, allowing inhibition of the downstream gene expression (Morsut et al., 2016; Witzgall et al., 1994).
IL-6 is found to play a major role in the pathophysiology of cytokine release syndrome (CRS), the most common adverse effect during CAR-T therapy (Shimabukuro-Vornhagen et al., 2018; Xiao et al., 2021). The elevated IL-6 during CAR-T therapy is mostly released by monocyte/macrophage cell lines induced by target cell pyroptosis upon T cell killing (Norelli et al., 2018; Shimabukuro-Vornhagen et al., 2018). Therefore, we created this device to set a negative ‘switch’ for CAR expression in the case of high serum IL-6 level. We hoped that this would help prevent severe CRS.
We expected that when the concentration of IL-6 is high, the binding of IL-6 with anti-IL-6 scFv would cause the Notch core domain to undergo proteolytic cleavages (Fig 1). As a result, the Gal4-KRAB domain would be released into the nucleus. We intended to express anti-CD19 CAR with UAS-pSV40 as the promoter in the CAR-T cells (see BBa_K4175012). Therefore, the DNA binding domain of Gal4 would bind to the UAS region, enabling the KRAB domain to inhibit the SV40 promoter. In this way, the expression of CAR would be inhibited. As the cytotoxicity effect of CAR-T cells would be weaker, the target cells would undergo less pyroptosis. Consequently, fewer monocytes/macrophages would be induced to release IL-6. The serum level of IL-6 would thus decrease.
When the concentration of IL-6 is low, IL-6R would fail to bind with IL-6 due to its low affinity. As the promoter upstream of CAR, pSV40, is a strong promoter, the CAR expression would be constitutive. Ideally, these would collectively allow the CAR-T cells to exert its cytotoxic effect under low IL-6 concentration (Fig 1).
Hopefully, these would help maintain the IL-6 level in a normal range during CAR-T therapy.
References
Morsut, L., Roybal, K.T., Xiong, X., Gordley, R.M., Coyle, S.M., Thomson, M., Lim, W.A., 2016. Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors. Cell 164, 780–791. https://doi.org/10.1016/j.cell.2016.01.012
Norelli, M., Camisa, B., Barbiera, G., Falcone, L., Purevdorj, A., Genua, M., Sanvito, F., Ponzoni, M., Doglioni, C., Cristofori, P., Traversari, C., Bordignon, C., Ciceri, F., Ostuni, R., Bonini, C., Casucci, M., Bondanza, A., 2018. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat. Med. 24, 739–748. https://doi.org/10.1038/s41591-018-0036-4
Shimabukuro-Vornhagen, A., Gödel, P., Subklewe, M., Stemmler, H.J., Schlößer, H.A., Schlaak, M., Kochanek, M., Böll, B., von Bergwelt-Baildon, M.S., 2018. Cytokine release syndrome. J. Immunother. Cancer 6, 56. https://doi.org/10.1186/s40425-018-0343-9
Witzgall, R., O’Leary, E., Leaf, A., Onaldi, D., Bonventre, J.V., 1994. The Krüppel-associated box-A (KRAB-A) domain of zinc finger proteins mediates transcriptional repression. Proc. Natl. Acad. Sci. U. S. A. 91, 4514–4518. https://doi.org/10.1073/pnas.91.10.4514
Xiao, X., Huang, S., Chen, S., Wang, Y., Sun, Q., Xu, X., Li, Y., 2021. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. J. Exp. Clin. Cancer Res. CR 40, 367. https://doi.org/10.1186/s13046-021-02148-6